BiotechTube

CT-L03 Group 1 + CT-L03 Group 2 + Placebo + Empagliflozin + Metformin

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

T2DM

Conditions

T2DM

Trial Timeline

Aug 27, 2024 → May 1, 2026

NCT ID
NCT06571591

About CT-L03 Group 1 + CT-L03 Group 2 + Placebo + Empagliflozin + Metformin

CT-L03 Group 1 + CT-L03 Group 2 + Placebo + Empagliflozin + Metformin is a phase 3 stage product being developed by Celltrion for T2DM. The current trial status is active. This product is registered under clinical trial identifier NCT06571591. Target conditions include T2DM.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06571591Phase 3Active

Competing Products

20 competing products in T2DM

See all competitors
ProductCompanyStageHype Score
MKP10241 + PlaceboMankind PharmaPhase 2
52
Metformin + Alogliptin + empagliflozinCelltrionPhase 3
77
L03RD1 + L03RD2 + CT-L03CelltrionPhase 1
33
DulaglutideEli LillyPhase 1
33
SHR-3167 + SHR-3167 PlaceboJiangsu Hengrui MedicinePhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tabletsAstraZenecaApproved
85
Dapagliflozin + Metformin XR + GlucophageAstraZenecaPhase 1
33
AZD8601+Placebo (SAD) + AZD8601+Placebo + Placebo+PlaceboAstraZenecaPhase 1
33
Saxagliptin 5 mg + Metformin XR 500 mg + Mertformin XR 2 x 500 mg + Komboglyze XR 5/500 mg + Komboglyze XR 5/1000 mgAstraZenecaPhase 1
33
Comparator: sitagliptin phosphate + Comparator: placebo (unspecified)MerckPhase 1
33
ErtugliflozinMerckPhase 1
33
Comparator: sitagliptin phosphate + Comparator: pioglitazone + Comparator: placebo to pioglitazone + Comparator: placebo to sitagliptinMerckPhase 1
33
Sitagliptin phosphate + Comparator: Sulfonylurea + MetforminMerckApproved
85
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day + comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/dayMerckPhase 3
77
Vildagliptin (LAF237) + Placebo + Insulin + MetforminNovartisApproved
85
LIK066 + PlaceboNovartisPhase 1/2
41
Vildagliptin + Metformin + sulfonylurea (SU) + Basal InsulinNovartisPhase 3
77
Maridebart cafraglutide + PlaceboAmgenPhase 3
76
Maridebart Cafraglutide + PlaceboAmgenPhase 2
51

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85